Virtual Library
Start Your Search
F. Galanternik
Author of
-
+
P2.01 - Advanced NSCLC (ID 618)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:00 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.01-007 - Molecular Characterization of Non-Small Cell Lung Cancers (NSCLC) in Young Patients from an Argentine Population (ID 7951)
09:00 - 09:00 | Author(s): F. Galanternik
- Abstract
Background:
NSCLC is the leading cause of cancer-related deaths in Argentina. NSCLC is rarely observed in young adults (aged 18-40 years) and presents distinctive molecular characteristics. This study analyzed the prevalence of oncogenic molecular alterations in tumor samples from young adults treated at our institution. Different molecular biology techniques were used and treatment outcomes were reported.
Method:
Retrospective observational study of FFPE tumor samples from individuals aged 18-40 years, presenting stage IV lung adenocarcinoma. ALK fusions were studied by IHC (clone-D5F3) and confirmed with FISH-Vysis. The areas selected for molecular studies were micro-dissected, and DNA/RNA were purified. EGFR mutations were studied by Sanger. If available, targeted NGS was done with Colon and Lung. Cancer Research Panel v2 (CLRP) for DNA analysis; and/or Oncomine™ Panel Focus Assay (OFA) for DNA/RNA analysis. Both panels were performed in an Ion 520 chip sequenced in the Ion S5 Next Generation Sequencing Systems. The sequences obtained were analyzed in the Ion Reporter™ Software 5.2.1. The OFA was informed by Ion Torrent™ Oncomine™ Knowledgebase Reporter.
Result:
Six patients were included, 5/6 tumors were lung adenocarcinoma and 1/6, poorly differentiated carcinoma. The male:female ratio was 2:1. Median age was 35y (range 32-37) and all subjects had stage IV disease. EGFR and ALK were tested in all patient's samples, and 4/6 had NGS analysis. Five samples (83%) harbored known targetable oncogenic drivers: EGFR sensitizing mutations occurred in 3/5, ALK translocation with KRAS co-mutation in 1/5, and HER2 exon 20 insertions in 1/5. Only one sample without NGS was negative for the studied oncogenes. Targeted therapies were administered to 4/5 patients. Figure 1
Conclusion:
Our series shows a high prevalence of known actionable oncogenic drivers in young patients with NSCLC tumor. In this population an extensive molecular profiling of tumors is required to improve the treatment strategy.
-
+
P2.02 - Biology/Pathology (ID 616)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Biology/Pathology
- Presentations: 1
- Moderators:
- Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P2.02-071 - Prospective Molecular Study of 22 Genes by NGS in Patients with Non-Small Cell Lung Cancer (NSCLC) in Argentina: A Single Institution Experience (ID 7950)
09:30 - 09:30 | Author(s): F. Galanternik
- Abstract
Background:
Next generation sequencing has contributed to understanding the biology of NSCLC and to improve therapy selection. The prevalence of other oncogenic alterations beyond EGFR, ALK and KRAS in Argentina remains unknown. The aim of this study was to characterize the genomic lanscape of NSCLC tumors from 45 patients in our institution by NGS.
Method:
Prospective observational study. We included 45 patients, over 18 years old, with diagnosis of NSCLC and adequate tumor sample. DNA was purified from FFPET samples. Targeted NGS was done with Colon and Lung Cancer Research Panel v2 (Ion Torrent™ AmpliSeq™ technology) for 22 genes with Ion 520 chip, sequenced in Ion S5 Next Generation Sequencing Systems.
Result:
Forte five patients were included in the analysis, 19 female (42%) and 26 male (58%). Median age was 57 years old (range 34-89). Most patients had lung adenocarcinoma 43 (96%), 1 squamous (2%) and 1 adenosquamous histology (2%). A total of 28 patients (62%) had stage IV lung cancer, 18% stage III, 4% stage II and 16% stage I. From 43 evaluable samples, 65 mutations were detected: TP53 n=21, KRAS n=20, EGFR n=9, BRAF n=5, MET n=3, ERBB2 n=2, FGFR3 n=2, PI3K n=2, FGFR2 n=1. Of these, 10 are associated with clinical benefit with approved targeted therapies. Two samples had novel EGFR mutations and 2 had EGFR co-activating mutations (Del19 + L858R; and G719C + S768I). KRAS and TP53 co-mutations were present in 50% of KRAS mutant samples. We encountered 26 variants of unknown significance. In our population, 37 samples (86%) had EGFR Q787Q (c.2361G>A) polymorphism.Figure 1
Conclusion:
The distribution of oncogene mutations in patients with NSCLC in our institution in Argentina is similar to other western countries with the exception of higher KRAS mutant patients in this cohort. An ongoing larger trial will provide further information for our country and the region.
